Aficamten shows potential to be first FDA-approved treatment for nonobstructive HCM - cardiovascularbusiness.com

Afficamten: Potential First FDA-Approved Treatment for Nonobstructive HCM

Aficamten shows potential to be the first FDA-approved treatment for nonobstructive HCM. (Source: cardiovascularbusiness.com)